Fly News Breaks for August 20, 2015
EVOK
Aug 20, 2015 | 06:06 EDT
Brean Capital analyst Difei Yang started shares of Evoke Pharma with a Buy rating and $13 price target. The company's EVK-001, in Phase III development for the treatment of gastroparesis, mitigates the negative side effects of oral metoclopramide and improves efficacy, Yang tells investors in a research note. The analyst views the probability of success of the ongoing Phase III trial as high.
News For EVOK From the Last 2 Days
There are no results for your query EVOK